Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,051,864
  • Shares Outstanding, K 296,660
  • Annual Sales, $ 452,480 K
  • Annual Income, $ 154,230 K
  • 36-Month Beta 2.10
  • Price/Sales 13.60
  • Price/Cash Flow 37.92
  • Price/Book 21.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.60 +4.08%
on 04/09/18
23.71 -13.96%
on 03/27/18
-2.31 (-10.17%)
since 03/23/18
3-Month
19.60 +4.08%
on 04/09/18
31.79 -35.83%
on 01/29/18
-10.08 (-33.07%)
since 01/24/18
52-Week
18.03 +13.14%
on 05/30/17
32.50 -37.23%
on 10/16/17
-0.90 (-4.23%)
since 04/24/17

Most Recent Stories

More News
Calithera's Kidney Cancer Candidate Gets Fast Track Status

Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.

LGND : 161.77 (-3.26%)
EXEL : 20.40 (-1.64%)
CALA : 5.90 (-0.42%)
BMY : 51.58 (+1.34%)
Shares of EXEL Down 24.2% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Exelixis Inc (NASDAQ:EXEL) on February 28th, 2018 at $26.69. In approximately 2 months, Exelixis Inc has returned 24.23% as of today's recent price of $20.22.

EXEL : 20.40 (-1.64%)
Exelixis to Release First Quarter 2018 Financial Results on Wednesday, May 2, 2018

Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter 2018 financial results will be released on Wednesday, May 2, 2018 after the markets close. At 5:00 p.m. EDT / 2:00...

EXEL : 20.40 (-1.64%)
Exelixis (EXEL) in Focus: Stock Moves 7.7% Higher

Exelixis (EXEL) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

BHVN : 26.43 (-7.26%)
EXEL : 20.40 (-1.64%)
Exelixis Elects Dr. Maria Freire to Its Board of Directors

Exelixis, Inc. (NASDAQ: EXEL) today announced that renowned biomedical research executive Maria C. Freire, Ph.D. has been elected to the company's Board of Directors. Dr. Freire's...

EXEL : 20.40 (-1.64%)
Exelixis Inc Has Returned 20.0% Since SmarTrend Recommendation (EXEL)

SmarTrend identified a Downtrend for Exelixis Inc (NASDAQ:EXEL) on February 28th, 2018 at $26.69. In approximately 1 month, Exelixis Inc has returned 19.99% as of today's recent price of $21.35.

EXEL : 20.40 (-1.64%)
Moving Average Crossover Alert: Exelixis, Inc. (EXEL)

Moving Average Crossover Alert: Exelixis, Inc. (EXEL)

EXEL : 20.40 (-1.64%)
Today's Research Reports on Trending Tickers: Exelixis and Galectin Therapeutics

NEW YORK, NY / ACCESSWIRE / April 5, 2018 / After falling sharply on global trade fears in early trading Wednesday, U.S. stocks rallied to close in the green. The Dow Jones Industrial Average touched...

GALT : 3.16 (-8.41%)
EXEL : 20.40 (-1.64%)
Weakness Seen in Exelixis (EXEL) Estimates: Should You Stay Away?

Exelixis (EXEL) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.

BHVN : 26.43 (-7.26%)
EXEL : 20.40 (-1.64%)
Wired News - Exelixis' Partner Ipsen Gets EMA Validation of the Application for a New Indication for CABOMETYX

Stock Monitor: ChemoCentryx Post Earnings Reporting

EXEL : 20.40 (-1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Key Turning Points

2nd Resistance Point 21.16
1st Resistance Point 20.78
Last Price 20.40
1st Support Level 20.12
2nd Support Level 19.84

See More

52-Week High 32.50
Fibonacci 61.8% 26.97
Fibonacci 50% 25.26
Fibonacci 38.2% 23.56
Last Price 20.40
52-Week Low 18.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar